Natera, Inc. (NASDAQ:NTRA) Stake Boosted by Williamson Legacy Group LLC

Williamson Legacy Group LLC increased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 3.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 8,994 shares of the medical research company’s stock after purchasing an additional 312 shares during the period. Natera accounts for 0.9% of Williamson Legacy Group LLC’s investment portfolio, making the stock its 16th biggest position. Williamson Legacy Group LLC’s holdings in Natera were worth $1,424,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Principal Securities Inc. lifted its stake in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. Gladstone Institutional Advisory LLC increased its position in Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after buying an additional 61 shares during the period. Silver Oak Securities Incorporated increased its position in Natera by 3.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after buying an additional 89 shares during the period. Covestor Ltd increased its position in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the period. Finally, Blue Trust Inc. increased its position in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Insider Activity at Natera

In related news, Director Roelof Botha sold 87,473 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total value of $14,793,433.76. Following the completion of the transaction, the director now owns 1,224,787 shares in the company, valued at $207,135,977.44. This trade represents a 6.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John Fesko sold 663 shares of the stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 295,772 shares of company stock worth $49,741,699 in the last quarter. 7.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday. JPMorgan Chase & Co. increased their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Piper Sandler increased their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Finally, Sanford C. Bernstein raised their price target on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average target price of $172.69.

Natera Price Performance

NASDAQ:NTRA opened at $155.59 on Friday. The business’s 50-day moving average price is $167.56 and its 200 day moving average price is $146.67. The firm has a market cap of $20.54 billion, a P/E ratio of -88.40 and a beta of 1.66. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.